A probe of Sanofi-owned Genzyme Corp. and subsidiary Genzyme do Brasil, under which they were accused of launching sham litigation to block competitors in the market for drugs that treat high phosphate levels in the blood, was closed today by the Brazilian competition authority's Tribunal.Members of the Tribunal of the Administrative Council